Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis, pain and inflammation.
Researchers from Institute of Medicinal Biotechnology have published details on the discovery of novel nonsteroidal farnesoid X receptor (FXR) agonists as potential therapeutic agents for the treatment of nonalcoholic steatohepatitis (NASH).
SFA Therapeutics Inc. has received FDA clearance of its IND application to investigate SFA-001N in patients with nonalcoholic steatohepatitis (NASH) with or without fibrosis.
Alagille syndrome (ALGS) is a rare JAG1 (encodes for a Notch ligand) autosomal dominant disease affecting approximately 1 in 30,000-40,000 individuals. ALGS developmental defects cause an absence of bile ducts (intrahepatic duct paucity, IHDP) with an inability to transport bile from the liver to bile ducts (cholestasis) as well as heart problems.
Obesity and chronic inflammation in the liver trigger the most severe form of nonalcoholic fatty liver disease (NAFLD), steatohepatitis. Scientists at the University of Texas (UT) have shown how damaged hepatocytes accumulated in the liver after a vicious cycle of cytokine expression induced shedding of a critical liver receptor.
Kyung Hee University and ST Pharm Co. Ltd. have patented ergostenol derivatives described as potentially useful for the treatment of inflammatory bowel disease (IBD).
Benevolentai Ltd. has submitted a clinical trial application (CTA) to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) for BEN-8744, an oral, peripherally restricted, small-molecule phosphodiesterase 10 (PDE10) inhibitor in development as a first-in-class treatment for ulcerative colitis.
Shenzhen Chipscreen Biosciences Ltd. has identified heterocyclic compounds acting as thyroid hormone receptor (THR) β agonists expected to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes, obesity, hyperlipidemia, hypothyroidism, atherosclerosis, thyroid cancer and hypercholesterolemia, among others.
The farnesoid X receptor (FXR), a bile acid receptor, plays a direct role regulating innate immune cells in the gut, and treating mice with an FXR agonist improved symptoms of inflammatory bowel disease (IBD). The findings provide a link between diet and innate immunity, and could lead to better ways to treat IBD. “The intestine is a major target for inflammation and inflammatory disease, particularly in the modern Western culture, where high-fat diets are becoming very prevalent,” Ronald Evans told BioWorld.
RSS
